Patent US3822978A successfully refreshed from Google Patents.
Patent US6074659A successfully refreshed from Google Patents.
US6074659A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic inhibitor of vascular smooth muscle cells
Assignee: UAB Research Foundation
•
Filing: 1998-07-10
•
Granted: 2000-06-13
•
Expires: 2018-07-10
Abstract
Abstract Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.
Inventors
- 👤 Lawrence L. Kunz
- 👤 Richard A. Klein
- 👤 John M. Reno
- 👤 David J. Grainger
- 👤 James C. Metcalfe
- 👤 Peter L. Weissberg
- 👤 Peter G. Anderson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 18:31
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K31/00; A61K31/13; A61K31/135; A61K31/138; A61K31/33; A61K31/335; A61K31/337; A61K31/395; A61K31/40; A61K31/4025; A61K31/403; A61K31/4035; A61K31/407; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6807; A61K47/6809; A61K47/6811; A61K47/6817; A61K47/6831; A61K47/6835; A61K47/6843; A61K47/69; A61K47/6921; A61K47/6927; A61K47/6929; A61K47/6931; G; G01; G01N; G01N2800/00; G01N2800/32; G01N2800/323
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
41 words
A therapeutic method, comprising treating procedural vascular trauma associated with placement of a device in a vessel by administering to a mammal a cytostatic amount of an agent that does not exhibit substantial cytotoxicity, wherein the agent is a cytoskeletal inhibitor.
Claim 2
Dependent Claim
41 words
A therapeutic method, comprising treating procedural vascular trauma associated with placement of a device in a vessel by administering to a mammal a cytostatic amount of an agent that does not exhibit substantial cytotoxicity, wherein the agent is a cytoskeletal inhibitor.
Claim 3
Dependent Claim
10 words
The method of claim 1 wherein the agent inhibits microtubules.
Claim 4
Dependent Claim
10 words
The method of claim 1 wherein the agent inhibits microfilaments.
Claim 5
Dependent Claim
11 words
The method of claim 1 wherein the agent inhibits actin polymerization.
Claim 6
Dependent Claim
15 words
The method of claim 1 wherein the agent is a cytochalasin or an analog thereof.
Claim 7
Dependent Claim
9 words
The method of claim 5 wherein cytochalasin is administered.
Claim 8
Dependent Claim
12 words
The method of claim 5 wherein an analog of cytochalasin is administered.
Claim 9
Dependent Claim
10 words
The method of claim 1 wherein the administration is local.
Claim 10
Dependent Claim
10 words
The method of claim 1 wherein the administration is systemic.
Claim 11
Dependent Claim
15 words
The method of claim 1 wherein the administration is before, during or after the trauma.
Claim 12
Dependent Claim
12 words
The method of claim 1 wherein the administration is during the trauma.
Claim 13
Dependent Claim
16 words
The method of claim 8, 10, or 11 wherein the delivery is accomplished by the device.
Claim 14
Dependent Claim
13 words
The method of claim 12 wherein the delivery is accomplished by a catheter.
Claim 15
Dependent Claim
18 words
The method of claim 1 wherein the amount is effective to inhibit migration of vascular smooth muscle cells.
Claim 16
Dependent Claim
13 words
The method of claim 12 wherein cytochalasin or an analog thereof is administered.
Claim 17
Dependent Claim
18 words
The method of claim 1 wherein the amount is effective to inhibit proliferation of vascular smooth muscle cells.
Claim 18
Dependent Claim
18 words
The method of claim 1 or 11 wherein the agent is administered in a sustained release dosage form.
Claim 19
Dependent Claim
14 words
The method of claim 17 wherein the agent is administered in a polymeric carrier.
Claim 20
Dependent Claim
13 words
The method of claim 11 wherein the sustained release dosage form is biodegradable.
Claim 21
Dependent Claim
23 words
The method of claim 1 or 8 wherein the agent is administered in a sustained release dosage form and delivered by the device.
Claim 22
Dependent Claim
32 words
The method of claim 17 wherein the sustained release form comprises a binding peptide or protein which specifically binds to smooth muscle cells, stromal cells or interstitial matrix surrounding smooth muscle cells.
Claim 23
Dependent Claim
15 words
The method of claim 2 wherein the sustained release dosage form comprises microparticles or nanoparticles.
Claim 24
Dependent Claim
24 words
The method of claim 22 wherein the sustained release dosage form comprises a polymer derived from the condensation of alpha-hydroxycarboxylic acids and related lactones.
Claim 25
Dependent Claim
27 words
The method of claim 23 wherein the polymer is selected from the group consisting of a polylactide, a polyglycolide, and a copolymer of lactide and glycolide subunits.
Claim 26
Dependent Claim
11 words
The method of claim 24 wherein the polymer is poly(lactide co-glycolide).
Claim 27
Dependent Claim
19 words
The method of claim 1 or 21 the vessel is subjected to angioplasty, placement of a stent, or grafting.
References Cited (Backward Citations)
US32944A
Cited
US33403A
Cited
US3940422A
Cited
US4070484A
Cited
USRE32944E
Cited
US4093709A
Cited
US4235988A
Cited
US5324736A
Cited
US5098903A
Cited
US4442119A
Cited
US5332584A
Cited
US4675189A
Cited
US5047431A
Cited
US4485096A
Cited
US5015666A
Cited
US4879315A
Cited
US4485097A
Cited
USRE33403E
Cited
US4512762A
Cited
US4577636A
Cited
US4555402A
Cited
US4867973A
Cited
US5226430A
Cited
US4897255A
Cited
US5284763A
Cited
US4824436A
Cited
US4826672A
Cited
US4744981A
Cited
US4906452A
Cited
US5316766A
Cited
US4935415A
Cited
US4859585A
Cited
US4962091A
Cited
US4879225A
Cited
US5314679A
Cited
EP0260066B1
Cited
US4839155A
Cited
US5120535A
Cited
US4968350A
Cited
US5114719A
Cited
US5093330A
Cited
EP0297946A2
Cited
US4835002A
Cited
US5216024A
Cited
US5221620A
Cited
US4929602A
Cited
US4997652A
Cited
US5468746A
Cited
US5213580A
Cited
US5066789A
Cited
US5208019A
Cited
US5340925A
Cited
US5268358A
Cited
US5032679A
Cited
US5380716A
Cited
US5304541A
Cited
US5015578A
Cited
US5073633A
Cited
US5356713A
Cited
US5364632A
Cited
US5026537A
Cited
US5288735A
Cited
US5248764A
Cited
US5208238A
Cited
US5364843A
Cited
US5346897A
Cited
US5395610A
Cited
US5242397A
Cited
US5112305A
Cited
US5043335A
Cited
EP0411893A3
Cited
US4990538A
Cited
US5059166A
Cited
US5176617A
Cited
US5232911A
Cited
US5049132A
Cited
US5199939B1
Cited
US5199939A
Cited
US5328471A
Cited
US5260224A
Cited
US5140012A
Cited
US5166143A
Cited
US5189046A
Cited
US5189212A
Cited
US5219548A
Cited
US5192525A
Cited
US5238714A
Cited
US5053033A
Cited
US5180366A
Cited
US5362424A
Cited
US5308622A
Cited
US5102402A
Cited
US5171217A
Cited
US5280016A
Cited
US5254594A
Cited
US5116864A
Cited
US5213576A
Cited
US5296492A
Cited
US5229495A
Cited
US5216126A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-06-13 | 2003-12-13 | 2004-06-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-06-13 | 2007-12-13 | 2008-06-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-06-13 | 2011-12-13 | 2012-06-13 | $7700.00 | Window Closed / Lapsed |